Halozyme Therapeutics is a biotechnology company developing and commercializing novel oncology therapies that target the tumor microenvironment.The lead proprietary program, our investigational drug PEGPH20, has a unique approach to target solid tumors, potentially increasing access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic and non-small cell lung cancers and has potential across additional cancers and types of therapies.